Malagueira Joao Paulo Falcao
Known title: DirectorCIK: 0001937552
Associated companies
Transaction History
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,749 | $0 | 6/16/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,749 | $79K | 6/17/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,065 | $210K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,749 | $0 | 6/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.